Fresh from the launch of its next-generation spinal tissue repair device, Anulex Technologies Inc. raised $3.8 million iun a debt and options sale to 11 investors, according to a regulatory filing.
Last month, Anulex began marketing a new version of its Xclose tissue repair device, which uses small, braided-polyester bands to make an X-shaped stitch over openings in the soft tissue around the spine. The device is designed to treat patients with herniated dics. The company says the device will keep discs from re-herniating and speed the recovery process.
The first-generation iteration of the Xclose was cleared for U.S. sale in general and orthopedic surgery in 2006. The device has been used in more than 7,300 procedures, according to Anulex.
The most recent cash infusion brings Anulex’s total funding to around $52 million since 2003. The company closed its fourth round of funding in June, pulling in $10.2 million from a number of investors. Affinity Capital, Delphi Ventures, MB Venture Partners, New Enterprise Associates, SightLine Partners and Split Rock Partners participated in that round.
The company is also developing a device called the InClose, a mesh implant designed to provide a scaffold to aid the re-growth of tissue after surgery.
An Anulex representative didn’t immediately return a call.
The company derives its name from the annulus, a term for the soft tissue that surrounds spinal discs.
